NCT01463813.

Trial name or title	The Finnish Vitamin D Trial (FIND)
Methods	Randomised, double‐blind, placebo‐controlled trial using parallel group design (3 intervention groups)
Participants	Country: Finland Estimated number of participants: 18,000 Inclusion criteria: men 60 years or older, women 65 years or older. Exclusion criteria: Cardiovascular disease (including myocardial infarction, stroke, transient ischaemic attack, angina pectoris, coronary artery bypass grafting, or percutaneous coronary intervention), cancer (except non‐melanoma skin cancer), any disease or state that raises a vitamin D‐related safety concern (such as chronic liver, thyroid or kidney disease, hypercalcaemia, sarcoidosis or other granulomatous diseases such as active chronic tuberculosis or Wegener's granulomatosis), use of supplements yielding vitamin D over 20 µg/day or calcium over 1200 mg/day and unwillingness to discontinue the use
Interventions	Participants will be randomly assigned to receive: Intervention group 1: vitamin D₃ (1600 IU) daily; Intervention group 1: vitamin D₃ (3000 IU) daily Comparator group: placebo daily for a period of 5 years
Outcomes	The primary outcome measure will be cancer and cardiovascular diseases
Starting date	January 2012; expected completion December 2019
Contact information	Tomi‐Pekka Tuomainen, MD, PhD 358 40 355 2956 tomi‐pekka.tuomainen@uef.fi Jyrki Virtanen, PhD 358 40 355 2957 jyrki.virtanen@uef.fi
Notes